Skip to content
PICO Portalanswers from OpenAlex

Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis

PaperCitations, authors & open-access status

Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis is a paper indexed in PICO Portal from OpenAlex.

How many citations does Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis have?

PICO Portalcitation count

Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis has 8 citations in the OpenAlex counts PICO Portal stores.

When was Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis published?

PICO Portalyear

Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis has 2024 year in the PICO Portal index.

What is the open-access status of Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis?

PICO Portaloa status

Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis has hybrid oa status in the PICO Portal index.

What is the DOI of Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis?

PICO Portaldoi

The DOI for Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis is on the source record.

What is the PMID of Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis?

PICO Portalpmid

The PMID for Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis is on the source record.

What is the OpenAlex record for Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis?

PICO Portalopenalex

The OpenAlex for Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial